Author: Editor

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute discusses whether or not early detection of metastasis can help overall survival in patients with breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Brian Rini, MD, Bernard Escudier, MD, James Larkin, MD and Cora N Sternberg, MD outline the challenges and Navigating the RCC Treatment Landscape: Learning from Experience at the 12th European International Kidney Cancer Symposium 2017

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine explains what types of tumors would the new drug be useful for? He argues that the new agent would be useful for all tumors since all tumors rely on a specialized metabolism in order to grow. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine discusses the treatment trends for 2017 which include combining therapy with targeting metabolism. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine explains the importance of targeting metabolism for cancer research. He argues by targeting metabolic pathways, selective tumor cells will be killed, which will enhance not only cancer treatments but immunotherapy as well. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine discusses his presentation topic, Immunometabolism in Immunotherapy, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses the treatment trends for 2017 in cancer, which includes immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute explains whether or not AURKA will play a role in melanoma treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses how the data from the AURKA study shows a possibility in combination therapy between MAPK pathway and other inhibitors. He states the future of clinical trials will revolve around this type of combination study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains the treatment trends for 2017, which include immunotherapy, t-cell therapy, and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains the significance of how tumors evolve from one type of mutation to another. He states that if there is a better understanding of tumor evolution and mutation, clinicians can gain an idea of what needs to be targeted in the future. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute discusses the process of manufacturing products for research at Roswell Park. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute discusses how the persistency of t-cell receptors against cancer can be achieved. He argues with this data, there will be more effective treatments for cancer and lower chances of relapse. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute gives an overview of his presentation, Sustained efficacy of immunotherapy for solid tumors with novel dual CD4/CD8 T cell receptor engineered synergistic combination of hematopoietic stem cells and T cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains how the new data on T-Cell receptors impacts next generation for immunotherapies. He argues how the harnessing of t-cell receptors to recognize cancer cells will benefit future clinical trials. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Evan W. Alley discusses the role of angioinhibition and immunotherapy in the treatment of mesothelioma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charles B. Simone, II elucidates use of IMRT, proton beam, or SBRT in LA-NSC radiation therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses attempts to integrate novel targeted agents and immunotherapy into the combined modality paradigm. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Tracey L. Evans discusses whether there are any options beyond chemoteray for non-small cell lung cancer (NSCLC) in the adjuvant setting. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charles B. Simone, II argues in favor of stereotactic body radiation therapy for early stage non-small cell lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Harvey I. Pass argues in favor of surgery for early stage non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Anil Vachani discusses when and how to intervene on a growing pulmonary module. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Anil Vachani discusses the impact of the National Lung Screen Trial. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Shakun M. Malik discusses novel protocol designs in the era of personalized lung cancer therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

Jürgen Gschwend, MD, PhD of the Technical University of Munich School of Medicine and Viktor Grünwald MD, PhD of the Hannover Medical School discuss Treating aRCC in Practice: Current and Future Perspectives at the Kidney Cancer European Symposium 2017.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the treatment trends for 2017. He explains the significance of immunotherapy, but also the potential for intratumoral therapy with combination therapy in future treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of presentations at AACR 2017 and explains the impact of these clinical presentations on future cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains whether or not there is a biomarker to better predict which patients respond to treatment. He states there have been studies for potential biomarkers, but none of the data showed significant responses. He advises all patients should undergo this treatment until clinicians find a biomarker. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains the impact of data on future research, stating that avelumab is the only FDA approved drug for Merkel Cell Carcinoma, and with moving forward, future research will involve immunotherapy and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the use of avelumab, a new agent that became available for patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the treatment trends in 2017 for patients with MDS and AML, which include introduction of new agents, combination therapy, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University explains how the impact of epigenetic therapy could lead to more randomized studies and new standard of care for patients with MDS and AML. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University gives an overview of presentations at AACR 2017, specifically on immunotherapy. He states that in order to make immunotherapy work better for patients, the idea of combining immunotherapy with epigenetic therapy is a possibility moving forward. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University gives an overview of his presentation, Epigenetic Therapy: What Is It, Where Are We, and What Does the Future Hold?, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses questions of concern on the the toxicity of the new epigenetic drugs and speculation on what happens after treatment with these drugs. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the importance of discovering and evaluating new epigenetic drugs for cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University gives an overview of his presentation, Mutational Landscapes of African American Colon Cancers. His presentation was a part of the ‘Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine’ session at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University explains how mutations in genes could potentially be used as biomarkers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University stresses the importance of finding data from diverse ethnic populations. He argues data from one population might not work or be affective for another. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University discusses the existing social stigmas for ethnic populations in cancer research. He hopes to educate healthcare professionals by removing these misconceptions which will ultimately benefit all diverse groups. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the use of combination therapy to extend duration of anti-androgen therapy response. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new clinical trials that can better assess patient response for treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new targets to treat Androgen Deprivation Therapy (ADT) Resistant Disease. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains whether or not variant cells pre-exist in tumors or if therapy causes these cells to transform. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the transformation of cancers into stem-cell phenotypes, which allows them to adapt to different therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics gives an overview of his abstract, Rb1 suppresses prostate cancer metastasis and lineage plasticity underlying castration resistance, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses the treatment trends for prostate cancer in 2017 and gives an overview of an AACR session, which focused on the “Hallmarks of Cancer” and the epigenetic phenomenon that is occurring in cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Toni Choueiri, MD and David McDermott, MD discusses the Immuno-Oncology: Changing the Treatment Landscape in RCC at the 12th European International Kidney Cancer Symposium 2017